The Hikma Pharmaceticals Board is recommending a final dividend of 34 cents per share (approximately 24 pence per share) (2019: 30 cents per share) bringing the total dividend for the full year to 50 cents per share (approximately 36 pence per share) (2019: 44 cents per share). The proposed dividend will be paid on 26 April 2021 to eligible shareholders on the register at the close of business on 19 March 2021, subject to approval at the Annual General Meeting on 23 April 2021.
Other financial highlights include:
Core Group revenue up 6%, reflecting growth in all three businesses
Core operating profit up 11%, driven by strong growth in profit of Generics and Injectables
Strong cashflow from operating activities of $464 million, whilst maintaining higher inventory levels to ensure continuity of supply during the COVID-19 pandemic
Continued investment in R&D of 6% of revenue, with growing pipeline of complex products
Healthy balance sheet, with net debt of $605 million and low leverage at 0.9x net debt to core EBITDA
